Published in J Exp Med on November 08, 2010
Gene copy-number alterations: a cost-benefit analysis. Cell (2013) 1.79
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemia. Blood (2012) 1.61
TGF-β - an excellent servant but a bad master. J Transl Med (2012) 1.41
New insights into the troubles of aneuploidy. Annu Rev Cell Dev Biol (2012) 1.36
The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies. J Cell Biol (2012) 1.17
C2ORF40 suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. Epigenetics (2013) 0.98
Targeting the adaptability of heterogeneous aneuploids. Cell (2015) 0.93
Whole chromosome aneuploidy: big mutations drive adaptation by phenotypic leap. Bioessays (2012) 0.93
Truncated form of TGF-βRII, but not its absence, induces memory CD8+ T cell expansion and lymphoproliferative disorder in mice. J Immunol (2013) 0.92
Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol (2015) 0.90
PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice. Haematologica (2012) 0.87
Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress. Proc Natl Acad Sci U S A (2014) 0.84
MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system. PLoS One (2014) 0.81
The DNA double-strand break response is abnormal in myeloblasts from patients with therapy-related acute myeloid leukemia. Leukemia (2013) 0.81
Co-operative leukemogenesis in acute myeloid leukemia and acute promyelocytic leukemia reveals C/EBPα as a common target of TRIB1 and PML/RARA. Haematologica (2016) 0.80
Notch signaling in acute promyelocytic leukemia. Leukemia (2013) 0.79
Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol (2015) 0.78
Inhibition of the intrinsic but not the extrinsic apoptosis pathway accelerates and drives MYC-driven tumorigenesis towards acute myeloid leukemia. PLoS One (2012) 0.78
Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma. Elife (2017) 0.75
The importance of molecular cytogenetic analysis prior to using cell lines in research: The case of the KG-1a leukemia cell line. Oncol Lett (2012) 0.75
PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias. Leukemia (2016) 0.75
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (1986) 14.56
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell (1999) 8.03
Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol (2005) 7.54
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev (2000) 6.54
Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol (1988) 6.51
c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev (2004) 5.83
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Definition of regions in human c-myc that are involved in transformation and nuclear localization. Mol Cell Biol (1987) 5.67
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature (1998) 5.30
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood (2001) 5.17
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A (2009) 4.17
Distinct thresholds govern Myc's biological output in vivo. Cancer Cell (2008) 4.16
Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77
Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci U S A (1999) 3.24
A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 3.20
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A (2001) 3.01
c-Myc represses transcription in vivo by a novel mechanism dependent on the initiator element and Myc box II. EMBO J (1994) 3.01
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature (2008) 2.95
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RARalpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1997) 2.75
High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples. J Clin Invest (2009) 2.66
The life cycle of C-myc: from synthesis to degradation. Cell Cycle (2004) 2.56
Role of the v-erbA and v-erbB oncogenes of avian erythroblastosis virus in erythroid cell transformation. Cell (1983) 2.08
c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood (2005) 1.96
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 1.92
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res (2005) 1.80
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
Focus on acute leukemias. Cancer Cell (2002) 1.67
Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia (1997) 1.66
Identification of a myeloid committed progenitor as the cancer-initiating cell in acute promyelocytic leukemia. Blood (2009) 1.61
Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis. Blood (2007) 1.55
Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice parallel human acute promyelocytic leukemia. Blood (2002) 1.54
Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping. Mol Cell Biol (1990) 1.38
Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol (2001) 1.33
Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations. Blood (2008) 1.30
MYC levels govern hematopoietic tumor type and latency in transgenic mice. Blood (2006) 1.16
PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors. Leukemia (2009) 1.16
Definition of the activities and properties of c-myc required to inhibit cell differentiation. Cell Growth Differ (1990) 1.14
MYC-containing double minutes in hematologic malignancies: evidence in favor of the episome model and exclusion of MYC as the target gene. Hum Mol Genet (2006) 1.13
FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. Br J Haematol (2007) 1.12
Nonrandom cytogenetic alterations in hepatocellular carcinoma from transgenic mice overexpressing c-Myc and transforming growth factor-alpha in the liver. Am J Pathol (1999) 1.09
A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep (2005) 1.09
Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene (1998) 1.07
CCAAT/Enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood (2002) 1.06
c-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol (2006) 1.03
Direct activation of HSP90A transcription by c-Myc contributes to c-Myc-induced transformation. J Biol Chem (2004) 1.00
Increased frequency of both total and specific monoclonal antibody producing hybridomas using a fusion partner that constitutively expresses recombinant IL-6. J Immunol Methods (1992) 0.97
TRIB1 overexpression in acute myeloid leukemia. Cancer Genet Cytogenet (2007) 0.91
How do retroviral oncogenes induce transformation in avian erythroid cells? Proc R Soc Lond B Biol Sci (1985) 0.83
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature (2007) 16.95
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell (2003) 11.40
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet (2005) 8.99
Senescence of activated stellate cells limits liver fibrosis. Cell (2008) 8.98
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Revised international prognostic scoring system for myelodysplastic syndromes. Blood (2012) 8.12
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med (2007) 7.75
A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell (2002) 6.76
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell (2002) 6.24
The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol (2007) 6.16
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice. Cancer Cell (2006) 5.88
An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet (2003) 5.82
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J (2003) 5.61
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science (2002) 5.47
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
miR-19 is a key oncogenic component of mir-17-92. Genes Dev (2009) 4.95
A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell (2006) 4.74
The microcosmos of cancer. Nature (2012) 4.50
Control of apoptosis by p53. Oncogene (2003) 4.46
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature (2004) 4.41
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A (2009) 4.15
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Bethesda proposals for classification of lymphoid neoplasms in mice. Blood (2002) 4.07
Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell (2008) 4.06
Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature (2006) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res (2009) 3.87
Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81
A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell (2011) 3.69
Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21. Nat Genet (2009) 3.59
Apoptosis and melanoma chemoresistance. Oncogene (2003) 3.58
Autophagy reduces acute ethanol-induced hepatotoxicity and steatosis in mice. Gastroenterology (2010) 3.57
Dissecting eIF4E action in tumorigenesis. Genes Dev (2007) 3.53
Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer (2009) 3.52
Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci U S A (2003) 3.46
A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol (2009) 3.44
RNAIII-independent target gene control by the agr quorum-sensing system: insight into the evolution of virulence regulation in Staphylococcus aureus. Mol Cell (2008) 3.44
Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci U S A (2004) 3.42
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol (2010) 3.33
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev (2011) 3.05
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A (2012) 3.03
p63 deficiency activates a program of cellular senescence and leads to accelerated aging. Genes Dev (2005) 3.02
Stem cells: The promises and perils of p53. Nature (2009) 3.01
Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol (2002) 3.00
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A (2007) 3.00
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Nix is critical to two distinct phases of mitophagy, reactive oxygen species-mediated autophagy induction and Parkin-ubiquitin-p62-mediated mitochondrial priming. J Biol Chem (2010) 2.93
A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proc Natl Acad Sci U S A (2012) 2.85
Functional identification of optimized RNAi triggers using a massively parallel sensor assay. Mol Cell (2011) 2.82
Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood (2003) 2.76
Mouse models of human AML accurately predict chemotherapy response. Genes Dev (2009) 2.75
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev (2008) 2.60
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell (2009) 2.54
Tissue-specific and reversible RNA interference in transgenic mice. Nat Genet (2007) 2.54
Bad-deficient mice develop diffuse large B cell lymphoma. Proc Natl Acad Sci U S A (2003) 2.54
Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54
Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci U S A (2008) 2.53
CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood (2012) 2.51
Shear stress induces endothelial differentiation from a murine embryonic mesenchymal progenitor cell line. Arterioscler Thromb Vasc Biol (2005) 2.51
Essential Staphylococcus aureus toxin export system. Nat Med (2013) 2.50
mTORC1 promotes survival through translational control of Mcl-1. Proc Natl Acad Sci U S A (2008) 2.50
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev (2012) 2.44
Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood (2004) 2.42
PML is a direct p53 target that modulates p53 effector functions. Mol Cell (2004) 2.40
Non-cell-autonomous tumor suppression by p53. Cell (2013) 2.40
Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest (2008) 2.40
Senescence comes of age. Nat Med (2005) 2.39
An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev (2011) 2.38
Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications. Cancer Res (2005) 2.37
Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J Surg (2009) 2.31